Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Kalra, Neetu ^a   Zhang, Jingli ^a   Thomas, Anish ^a   Xi, Liqiang ^a   Cheung, Mitchell ^b   Talarchek, Jacqueline ^b   Burkett, Sandra ^c   Tsokos, Maria G ^d   Chen, Yuanbin ^a   Raffeld, Mark ^a   Miettinen, Markku ^a   Pastan, Ira ^a   Testa, Joseph R ^b   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BAP1; CDKN2A; Malignant effusions; Mesothelioma; Patient derived tumor xenografts

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; NEUROFIBROMIN; PROTEIN P53; TUMOR MARKER; UBIQUITIN THIOLESTERASE; UVOMORULIN; VIMENTIN; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES FLUID; BAP1 GENE; CANCER MORPHOLOGY; CDKN2A GENE; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FRAMESHIFT MUTATION; GENE DELETION; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KARYOTYPE; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIOMA CELL LINE; MIDDLE AGED; MISSENSE MUTATION; MOUSE; MUTATIONAL ANALYSIS; NF2 GENE; NONHUMAN; PRIMARY CELL CULTURE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; YOUNG ADULT; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE TECHNIQUE; EXPERIMENTAL NEOPLASM; GENETICS; LUNG TUMOR; MESOTHELIOMA; MUTATION; NUDE MOUSE; PATHOLOGY; PLEURA TUMOR; SCID MOUSE; TUMOR CELL CULTURE;

AGED; ANIMALS; CELL CULTURE TECHNIQUES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MICE; MICE, NUDE; MICE, SCID; MIDDLE AGED; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PLEURAL NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

EID: 84929339541     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1362-2     Document Type: Article

References (32)

1. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13(7):e301-10.
2. Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, Ardizzoni A, et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J. 1999;13(3):527-34.
3. Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97(5):387-94.
4. Kobayashi M, Takeuchi T, Ohtsuki Y. Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status. Anticancer Res. 2008;28(1A):197-208.
5. Shimosato Y, Kameya T, Najai K, Hirohashi S, Koide T, Hayashi H, et al. Transplantation of human tumors in nude mice. J Natl Cancer Inst. 1976;56(6):1251-60.
6. Relan V, Morrison L, Parsonson K, Clarke BE, Duhig EE, Windsor MN, et al. Phenotypes and karyotypes of human malignant mesothelioma cell lines. PLoS One. 2013;8(3):e58132.
7. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 1994;54(21):5547-51.
8. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A. 1995;92(24):10854-8.
9. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227-31.
10. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-72.
11. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022-5.
12. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res. 2008;68(17):6953-62.
13. Kalra N, Ashai A, Xi L, Zhang J, Avital I, Raffeld M, et al. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors. Oncol Rep. 2012;27(6):1794-800.
14. Mohamedali A, Lea NC, Feakins RM, Raj K, Mufti GJ, Kocher HM. AKT1 (E17K) mutation in pancreatic cancer. Technol Cancer Res Treat. 2008;7(5):407-8.
15. Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(4):3330-2.
16. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011;13(1):74-84.
17. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7(3):396-403.
18. Chowdhuri SR, Xi L, Pham TH, Hanson J, Rodriguez-Canales J, Berman A, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol. 2012;25(4):548-55.
19. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008;10(6):534-41.
20. Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med. 2008;14(5):579-84.
21. Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res. 2012;32(12):5151-8.
22. Parson W, Kirchebner R, Mühlmann R, Renner K, Kofler A, Schmidt S, et al. Cancer cell line identification by short tandem repeat profiling: power and limitations. FASEB J. 2005;19(3):434-6.
23. Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer. 1989;1(2):148-54.
24. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene. 1995;11(3):511-5.
25. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst. 1995;87(24):1870-5.
26. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9(6):2108-13.
27. Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, et al. Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg. 1995;59(4):835-44.
28. Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012;103(5):868-74.
29. Chung CT, Santos Gda C, Hwang DM, Ludovski O, Pintilie M, Squire JA, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63(7):630-4.
30. Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, et al. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One. 2011;6(4):e18828.
31. Lee WC, Balsara B, Liu Z, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res. 1996;56(19):4297-301.
32. Tsujimura T, Torii I, Sato A, Song M, Fukuoka K, Hasegawa S, et al. Pathological and molecular biological approaches to early mesothelioma. Int J Clin Oncol. 2012;17(1):40-7.